Xarelto is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1]. Its manufacturing operations are a global network.
What facilities produce Xarelto?
While specific details on every Xarelto manufacturing site are not publicly disclosed, production is managed through Johnson & Johnson's extensive pharmaceutical manufacturing infrastructure. This includes facilities involved in the synthesis of active pharmaceutical ingredients and the formulation and packaging of the final drug product [1].
Who developed Xarelto and when?
Xarelto (rivaroxaban) was developed through a collaboration between Bayer AG and Janssen Pharmaceuticals [2]. The drug received its initial approval from the U.S. Food and Drug Administration (FDA) in 2011 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation [3].
When does Xarelto's patent expire?
Patent exclusivity for Xarelto has been a complex area. Various patents cover different aspects of the drug, including its composition of matter, methods of use, and manufacturing processes. Exclusivity periods can vary by country and by specific patent. Information on the expiration of patents related to Xarelto can be found on specialized databases like DrugPatentWatch.com [4].
Can generic versions of Xarelto be made before patents expire?
Generally, generic versions of a drug cannot be legally marketed until the relevant patents protecting the drug expire or are successfully challenged. For Xarelto, the timeline for generic entry depends on the resolution of ongoing patent litigation and the expiration dates of key patents.
What is Xarelto used for?
Xarelto is an anticoagulant, commonly known as a blood thinner. It is prescribed to prevent blood clots in several conditions, including stroke and systemic embolism in patients with atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE) [3]. It is also used to reduce the risk of DVT and PE in patients who have undergone hip or knee replacement surgery.